Enovis Corporation

Valuation Analysis

About the Company

Enovis Corporation en bref

Enovis Corporation (ENOV) is currently trading at 19,15 € with a market capitalization of 1,1 Md €. The 52-week range spans from 17,91 € to 32,10 €; the current price is 40.3% below the yearly high. Year-over-year revenue growth stands at +5.4%.

💰 Dividende

Enovis Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent Enovis Corporation (ENOV) au consensus : Achat Fort. L'objectif de cours moyen est de 37,49 €, soit un potentiel de +95.72% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 28,77 € à 47,95 €.

Enovis Corporation : la thèse d'investissement en détail

Enovis Corporation (ENOV) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 61%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 95.72% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 17.92% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

At a PEG of 3.45, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 7.04x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 95.72% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility, elevated short interest (17.92%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Enovis Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.